Phase 2 Study of Surovatamig AZD0486 IV Treatment in Adults With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Including Follicular and Large B-Cell Lymphoma

What this Trial Is About

Researchers are evaluating surovatamig AZD0486 monotherapy in adults with relapsed or refractory B-cell non-Hodgkin lymphoma NHL who have previously received at least two different treatments. This Phase 2, global, multi-center, open-label study includes two modules one for follicular lymphoma FL and another for large B-cell lymphoma LBCL. The goal is to assess the efficacy, safety, and tolerability of surovatamig at the recommended Phase 2 dose RP2D. Participants receive surovatamig as an intravenous infusion in both modules. Module 1 focuses on relapsedrefractory FL, and Module 2 on relapsedrefractory LBCL. The study is single-arm and open-label, meaning all participants receive the study drug. Treatment is given in repeated 28-day cycles, with dosing and safety monitored throughout the treatment period. During the study, participants undergo regular assessments including scans to measure tumor response, blood tests to monitor drug levels and safety, and evaluations for side effects. The primary outcome is the overall response rate assessed up to approximately 24 months for Module 1 and 12 months for Module 2. Secondary outcomes include duration of response, survival measures, and quality of life assessments, with follow-up lasting up to about 5 years to monitor long-term effects and safety.

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL